Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP opened at $2.15 on Friday. The business’s 50-day moving average price is $2.25 and its two-hundred day moving average price is $2.31. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.09. The company has a market capitalization of $87.83 million, a P/E ratio of 19.55 and a beta of 1.65.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.16). The business had revenue of $2.00 million during the quarter. On average, equities analysts anticipate that Oramed Pharmaceuticals will post -0.03 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. N.E.W. Advisory Services LLC grew its stake in Oramed Pharmaceuticals by 52.9% in the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 6,540 shares in the last quarter. World Equity Group Inc. bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth about $48,000. Dimensional Fund Advisors LP boosted its stake in shares of Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth about $550,000. Finally, Boothbay Fund Management LLC boosted its stake in shares of Oramed Pharmaceuticals by 2.0% during the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after acquiring an additional 16,857 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.